company background image
SLGL

Sol-Gel Technologies NasdaqGM:SLGL Stock Report

Last Price

US$5.17

Market Cap

US$119.6m

7D

0.2%

1Y

-31.0%

Updated

05 Feb, 2023

Data

Company Financials +

Sol-Gel Technologies Ltd.

NasdaqGM:SLGL Stock Report

Mkt Cap: US$119.6m

SLGL Stock Overview

Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel.

SLGL fundamental analysis
Snowflake Score
Valuation3/6
Future Growth5/6
Past Performance3/6
Financial Health6/6
Dividends0/6

Rewards

Trading at 70.5% below our estimate of its fair value

Earnings are forecast to grow 54.98% per year

Became profitable this year

Risk Analysis

No risks detected for SLGL from our risk checks.

My Notes

New

Notes are coming soon

Sol-Gel Technologies Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Sol-Gel Technologies
Historical stock prices
Current Share PriceUS$5.17
52 Week HighUS$8.08
52 Week LowUS$3.94
Beta1.28
1 Month Change20.79%
3 Month Change8.61%
1 Year Change-30.97%
3 Year Change-52.48%
5 Year Change-51.23%
Change since IPO-62.10%

Recent News & Updates

Recent updates

Sol-Gel Technologies GAAP EPS of $0.01 beats by $0.11, revenue of $3.5M misses by $1.11M

Aug 04

These Analysts Think Sol-Gel Technologies Ltd.'s (NASDAQ:SLGL) Sales Are Under Threat

May 17
These Analysts Think Sol-Gel Technologies Ltd.'s (NASDAQ:SLGL) Sales Are Under Threat

We Think That There Are Issues Underlying Sol-Gel Technologies' (NASDAQ:SLGL) Earnings

Apr 15
We Think That There Are Issues Underlying Sol-Gel Technologies' (NASDAQ:SLGL) Earnings

Downgrade: Here's How Analysts See Sol-Gel Technologies Ltd. (NASDAQ:SLGL) Performing In The Near Term

Apr 05
Downgrade: Here's How Analysts See Sol-Gel Technologies Ltd. (NASDAQ:SLGL) Performing In The Near Term

We Think Sol-Gel Technologies (NASDAQ:SLGL) Can Afford To Drive Business Growth

Nov 23
We Think Sol-Gel Technologies (NASDAQ:SLGL) Can Afford To Drive Business Growth

We Think Sol-Gel Technologies (NASDAQ:SLGL) Needs To Drive Business Growth Carefully

Aug 04
We Think Sol-Gel Technologies (NASDAQ:SLGL) Needs To Drive Business Growth Carefully

Here's Why Sol-Gel Technologies Ltd.'s (NASDAQ:SLGL) CEO May Deserve A Raise

Jul 01
Here's Why Sol-Gel Technologies Ltd.'s (NASDAQ:SLGL) CEO May Deserve A Raise

Sol-Gel says no FDA notification regarding its marketing application for EPSOLAY

Apr 27

Newsflash: Sol-Gel Technologies Ltd. (NASDAQ:SLGL) Analysts Have Been Trimming Their Revenue Forecasts

Mar 05
Newsflash: Sol-Gel Technologies Ltd. (NASDAQ:SLGL) Analysts Have Been Trimming Their Revenue Forecasts

We're Not Very Worried About Sol-Gel Technologies' (NASDAQ:SLGL) Cash Burn Rate

Feb 02
We're Not Very Worried About Sol-Gel Technologies' (NASDAQ:SLGL) Cash Burn Rate

What Type Of Returns Would Sol-Gel Technologies'(NASDAQ:SLGL) Shareholders Have Earned If They Purchased Their SharesYear Ago?

Dec 29
What Type Of Returns Would Sol-Gel Technologies'(NASDAQ:SLGL) Shareholders Have Earned If They Purchased Their SharesYear Ago?

FDA accepts Sol-Gel application for Twyneo

Dec 07

Sol-Gel: Slow And Steady Topical Technology

Nov 19

These Analysts Think Sol-Gel Technologies Ltd.'s (NASDAQ:SLGL) Sales Are Under Threat

Nov 18
These Analysts Think Sol-Gel Technologies Ltd.'s (NASDAQ:SLGL) Sales Are Under Threat

Sol-Gel Technologies EPS beats by $0.09, beats on revenue

Nov 12

Shareholder Returns

SLGLUS PharmaceuticalsUS Market
7D0.2%-0.5%1.7%
1Y-31.0%4.6%-9.6%

Return vs Industry: SLGL underperformed the US Pharmaceuticals industry which returned 4.6% over the past year.

Return vs Market: SLGL underperformed the US Market which returned -9.6% over the past year.

Price Volatility

Is SLGL's price volatile compared to industry and market?
SLGL volatility
SLGL Average Weekly Movement7.5%
Pharmaceuticals Industry Average Movement11.5%
Market Average Movement6.7%
10% most volatile stocks in US Market17.5%
10% least volatile stocks in US Market2.8%

Stable Share Price: SLGL is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: SLGL's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
199753Alon Seri-Levyhttps://www.sol-gel.com

Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company’s lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay, a once-daily topical cream that has completed Phase III clinical trials for the treatment of papulopustular rosacea; SGT-210, which is in Phase I clinical trial for the treatment of palmoplantar keratoderma; and Erlotinib, Tapinarof, and roflumilast to treat psoriasis and other medical conditions. It is also involved in the development of generic topical dermatological drug products.

Sol-Gel Technologies Ltd. Fundamentals Summary

How do Sol-Gel Technologies's earnings and revenue compare to its market cap?
SLGL fundamental statistics
Market CapUS$119.58m
Earnings (TTM)US$4.89m
Revenue (TTM)US$24.59m

24.4x

P/E Ratio

4.9x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
SLGL income statement (TTM)
RevenueUS$24.59m
Cost of RevenueUS$13.46m
Gross ProfitUS$11.13m
Other ExpensesUS$6.24m
EarningsUS$4.89m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)0.21
Gross Margin45.27%
Net Profit Margin19.90%
Debt/Equity Ratio0%

How did SLGL perform over the long term?

See historical performance and comparison